This company has been acquired
Surface Oncology Management
Management criteria checks 3/4
Surface Oncology's CEO is Rob Ross, appointed in Apr 2021, has a tenure of 2.42 years. total yearly compensation is $1.92M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $89.02K. The average tenure of the management team and the board of directors is 2.4 years and 4.7 years respectively.
Key information
Rob Ross
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 29.5% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.4yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically
Nov 07
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts
Aug 08Surface Oncology GAAP EPS of -$0.46 misses by $0.01
Aug 03Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
May 25News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
May 11Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 23Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Jan 18Is Surface Oncology (NASDAQ:SURF) A Risky Investment?
Nov 11Surface Oncology: Staying The Course
Oct 24Surface Oncology: A Diverse, But Early Pipeline
Jul 13Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Jun 07Surface Oncology EPS beats by $0.04, beats on revenue
May 05Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like
Mar 15Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 16
Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets
Dec 09What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?
Dec 08Surface Oncology shares rise 13% on Fast Track tag for SRF388
Nov 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$93m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$2m | US$568k | -US$64m |
| Sep 30 2022 | n/a | n/a | -US$66m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$57m |
| Dec 31 2021 | US$5m | US$506k | -US$78m |
| Sep 30 2021 | n/a | n/a | US$13m |
| Jun 30 2021 | n/a | n/a | US$17m |
| Mar 31 2021 | n/a | n/a | US$21m |
| Dec 31 2020 | US$1m | US$435k | US$59m |
| Sep 30 2020 | n/a | n/a | -US$24m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$810k | US$400k | -US$55m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$35m |
| Dec 31 2018 | US$880k | US$361k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$15m |
| Mar 31 2018 | n/a | n/a | -US$13m |
| Dec 31 2017 | US$467k | US$329k | -US$45m |
Compensation vs Market: Rob's total compensation ($USD1.92M) is above average for companies of similar size in the US market ($USD763.55K).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Ross (49 yo)
2.4yrs
Tenure
US$1,924,455
Compensation
Dr. Robert W. Ross, also known as Rob, M.D., is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Independent Director at Xilio Therapeutics, Inc....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.4yrs | US$1.92m | 0.14% $ 89.0k | |
| Chief Medical Officer | 3.6yrs | US$1.06m | no data | |
| CFO & Treasurer | 4.8yrs | no data | 0.17% $ 109.1k | |
| Deputy General Counsel & Secretary | less than a year | no data | 0.051% $ 33.1k | |
| Chief People Officer | no data | no data | no data | |
| Senior Vice President of Development Operations | 1.8yrs | no data | no data |
2.4yrs
Average Tenure
52yo
Average Age
Experienced Management: SURF's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.4yrs | US$1.92m | 0.14% $ 89.0k | |
| Independent Member of Scientific Advisory Board & Director | 5.6yrs | US$80.57k | 0.075% $ 48.6k | |
| Independent Director | 9.4yrs | US$84.57k | 0% $ 0 | |
| Director | 5.6yrs | US$72.57k | 0.21% $ 138.3k | |
| Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
| Independent Director | 8.8yrs | US$89.07k | 0% $ 0 | |
| Independent Director | 5.6yrs | US$92.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman & Lead Independent Director | 2.2yrs | US$151.82k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.7yrs | no data | no data |
4.7yrs
Average Tenure
55yo
Average Age
Experienced Board: SURF's board of directors are considered experienced (4.7 years average tenure).